The New Tvm Life Science Ventures Vi Lp Holding in Albireo Pharma, Inc
Tvm Life Science Ventures Vi Lp filed with the SEC SC 13D form for Albireo Pharma, Inc. The form can be accessed here: 000107261316000969. As reported in Tvm Life Science Ventures Vi Lp’s form, the filler as of late owns 9.9% or 621,761 shares of the Health Care–company.
Albireo Pharma, Inc stake is a new one for the and it was filed because of activity on November 3, 2016. We feel this shows Tvm Life Science Ventures Vi Lp’s positive view for the stock.
Reasons Why Tvm Life Science Ventures Vi Lp Bought – Albireo Pharma, Inc Stock
Purpose of Transaction
TVM VI Cayman acquired the TVM VI Cayman Shares and TVM VI German acquired the TVM VI German Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, TVM VI Cayman, TVM VI German and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:
|(a)||The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;|
|(b)||An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;|
|(c)||A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;|
|(d)||Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;|
|(e)||Any material change in the present capitalization or dividend policy of the Issuer;|
|(f)||Any other material change in the Issuer’s business or corporate structure;|
|(g)||Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;|
|(h)||Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;|
|(i)||A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section12(g)(4) of the Securities Exchange Act of 1934; or|
|(j)||Any action similar to any of those enumerated above.|
Albireo Pharma, Inc Institutional Sentiment
Latest Security and Exchange filings show 34 investors own Albireo Pharma, Inc. The institutional ownership in Q3 2015 is low, at 60.66% of the outstanding shares. This is increased by 1418309 the total institutional shares. 38916338 were the shares owned by these institutional investors. In total 2 funds opened new Albireo Pharma, Inc stakes, 5 increased stakes. There were 10 that closed positions and 16 reduced them.
Rock Springs Capital Management Lp is an institutional investor bullish on Albireo Pharma, Inc, owning 4000000 shares as of Q3 2015 for 0.14% of its portfolio. Kevin Kotler Broadfin Capital Llc owns 5155530 shares or 0.13% of its portfolio. CA Longwood Capital Partners Llc have 0.65% of their stock portfolio for 2548830 shares. Further, Awm Investment Company Inc reported stake worth 0.38% of its US stock portfolio. The CT Great Point Partners Llc owns 3316966 shares. Albireo Pharma, Inc is 0.58% of the manager’s US portfolio.
Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Its clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. Its pipeline includes A4250, A3384 and Elobixibat. The Company is developing A4250 as a treatment for pediatric orphan cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC). The Company is developing A3384 for the treatment of bile acid malabsorption (BAM) disease. The Company is also developing Elobixibat as a treatment for chronic idiopathic constipation (CIC). A4250 and Elobixibat are selective inhibitors of the ileal bile acid transporter (IBAT). The Company has completed a Phase II clinical trial of a prototype of A3384 in over 19 subjects with BAM.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 0.64 in Q2 2016. Its up 0.14, from 0.5 in 2016Q1. The ratio is positive, as 6 funds sold all Albireo Pharma Inc shares owned while 5 reduced positions. 1 funds bought stakes while 6 increased positions. They now own 5.68 million shares or 19.38% less from 7.05 million shares in 2016Q1.
Geode Cap Management Lc last reported 0% of its portfolio in the stock. Finemark National Bank & Trust Tru last reported 0% of its portfolio in the stock. Moreover, Citadel Llc has 0% invested in Albireo Pharma Inc (NASDAQ:BIOD) for 74,155 shares. Moreover, Group Inc One Trading Limited Partnership has 0% invested in Albireo Pharma Inc (NASDAQ:BIOD) for 60,628 shares. Blackrock Institutional Na last reported 25,914 shares in the company. The Pennsylvania-based Vanguard Gp Inc has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD). Acadian Asset Management Limited Co holds 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD) for 37,389 shares. Blackrock Fund Advsr reported 11,195 shares or 0% of all its holdings. Renaissance Lc holds 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD) for 3.57 million shares. Ladenburg Thalmann Service accumulated 0% or 1,000 shares. Kcg has 68,782 shares for 0% of their US portfolio. Ameriprise has 12,300 shares for 0% of their US portfolio. Creative Planning last reported 150 shares in the company. Moreover, Psagot Invest House has 0% invested in Albireo Pharma Inc (NASDAQ:BIOD) for 71,000 shares. The Michigan-based Plante Moran Fincl Advsrs Llc has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD).
Analysts await Albireo Pharma Inc (NASDAQ:BIOD) to report earnings on December, 15.
The stock closed at $19.46 during the last session. It is down 80.56% since April 4, 2016 and is uptrending. It has outperformed by 75.57% the S&P500.
Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.25 billion. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. It currently has negative earnings. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate.
Albireo Pharma Inc (NASDAQ:BIOD) Ratings Coverage
Out of 2 analysts covering Biodel (NASDAQ:BIOD), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Biodel has been the topic of 2 analyst reports since December 18, 2015 according to StockzIntelligence Inc. As per Friday, December 18, the company rating was downgraded by Ladenburg Thalmann. The rating was downgraded by William Blair on Friday, December 18 to “Market Perform”.
More notable recent Albireo Pharma Inc (NASDAQ:BIOD) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 05, 2016, also Streetinsider.com with their article: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” published on November 07, 2016, Streetinsider.com published: “Form 4 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Zorn Peter A” on November 07, 2016. More interesting news about Albireo Pharma Inc (NASDAQ:BIOD) were released by: Marketwired.com and their article: “Biodel Inc. and Albireo Limited Agree to Combine” published on May 25, 2016 as well as Globenewswire.com‘s news article titled: “Albireo Completes Transaction with Biodel to Create Publicly Traded Company …” with publication date: November 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.